| Ytd | -37.28% | |
| 1y | -60.67% |
| Open | 0.35 | Prev Close | 0.34 | Low | 0.34 | High | 0.35 | Mkt Cap | 7.70M |
| Vol | 40.65K | Avg Vol | 615.14K | EPS | -0.47 | P/E | -0.74 | Forward P/E | -6.39 |
| Beta | 4.00 | Short Ratio | 0.56 | Inst. Own | 2.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.42 | 200-d Avg | 0.61 | 1yr Est | 3.00 |
NXL News
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-mar
Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-mar
Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clin
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinica
Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-m
Newly issued U.S. patent expected to provide core intellectual property protection through 2042, fur
U.S. House Appropriations Committee report language directs VA to support additional research evalua
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture
Publication reports statistically significant improvement in sleep quality following treatment with
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submi
HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on A
IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline
BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and
Nexalin Technology (NASDAQ: NXL - Get Free Report) and Algorhythm (NASDAQ: RIME - Get Free Report) a
Nexalin Technology, Inc. (NASDAQ: NXL - Get Free Report) saw a significant decline in short interest
150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lin
Nexalin Participates in & Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulat
New digital health platform being launched in partnership with UCSD allows remote physician-monitore
Nexalin launched its AI-powered NeuroCare virtual clinic with UC San Diego, enabling at-home brain t
HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”
Nexalin Technology, Inc. (NASDAQ: NXL - Get Free Report)'s stock price traded up 1% during trading o
HOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the co
Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted be
Wednesday's session saw 150 companies set new 52-week lows.
During Friday's trading, 293 companies set new 52-week lows.
On Thursday, 930 stocks hit new 52-week lows.
Monday saw 825 companies set new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.